Radiologist resistance to three-dimensional image processing plaguesthe medical 3-D industry segment. That's not new. However, weakclinical demand for 3-D products combined with a general downturnin hospital purchasing of high-end imaging equipment has
Radiologist resistance to three-dimensional image processing plaguesthe medical 3-D industry segment. That's not new. However, weakclinical demand for 3-D products combined with a general downturnin hospital purchasing of high-end imaging equipment has aimeda killer punch at the 3-D business. The market's punch provedtoo much for Reality Imaging, a six-year-old firm sprung fromthe ashes of Technicare's 3-D effort (SCAN 8/17/88).
Reality will shortly close its doors, confirmed president RobertH. Wake. Prior to joining Reality at its start, Wake served asvice president of engineering at Technicare, Johnson & Johnson'smedical imaging subsidiary that closed in 1986.
Solon, OH-based Reality was formed to commercialize Technicare'sVoxel Flinger 3-D workstation. It fell victim to an underachievingmarket coupled with belt-tightening by OEMs, the primary customersfor Reality's technology, Wake said.
Reality and other companies had projected an annual marketof 500 units for 3-D-capable workstations. The market demand neverexceeded much more than 100 units, Wake said.
"If the market had reached those kinds of numbers we'dbe able to weather a momentary problem like this," he said."It's no secret that this whole niche is really struggling.No one has made money in the workstation business, particularlyin the 3-D workstation segment."
This factor combined with OEM cutbacks to drive the nail inthe coffin, Wake told SCAN.
"When scanner sales start getting tight, the OEMs startcutting back even more stringently in other areas," he said.
The Japanese market segment, which accounted for a large fractionof Reality's sales, has also remained stagnant, Wake said.
"Japan's economy is still shaky, at least psychologically,"he said.
Privately held Cemax of Fremont, CA, claims it has experiencedrapid revenue growth and profits from OEM software sales (SCAN2/10/93 and 6/30/93). Cemax switched several years ago from thesupply of proprietary 3-D workstations to sell image processingand management software that runs on standard Sun Microsystemsworkstations.
ISG Technologies has also had relative success as an independent3-D workstation supplier, although it continues to lose money.The Toronto firm has branched out into related product areas,including development of a 3-D surgical viewing wand. ISG hasbeen publicly listed on the Toronto Stock Exchange since 1986and obtained an additional listing on the U.S. NASDAQ stock exchangelast year.
ISG lost $326,000 in the third quarter (end-March) of fiscal1993, an increase from its loss of $246,000 in the third quarterof 1992. Fourth quarter and full-year results are due out thisweek. Late last year ISG extended a long-standing 3-D supply arrangementwith Philips Medical Systems for an additional five years.
While the specifics have not yet been finalized, Reality willlikely declare Chapter 7 (dissolution) under bankruptcy laws.If the company garners enough cash from sales of its technologyto pay off its creditors, however, it will not go that route,Wake said.
"You only declare bankruptcy if you can't pay all yourcreditors," he said. "We may or may not pay all of ourcreditors."
A decision on whether to declare Chapter 7 will probably bemade within a few weeks, Wake said.
Reality is selling the software for its Voxel Flinger workstationto two groups that will maintain its installed base of about 60units. One of those groups already owns a large percentage ofthe installed base, while the other will be covering the rest,Wake said.
Wake plans to remain in medical imaging, although he's notsure in what area.
"Rationally, given the state of the market, this is thewrong business to be in," Wake said. "Emotionally, though,I have so many ties to medical imaging that I know I'll stay inthe business."
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.